Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Summer Solstice & Extra Daylight for AMD Patients with a New Potential Treatment Option

Needham & Company reiterates a 'Buy' on Regeneron Pharma (NASDAQ: REGN),

Needham analyst says, "In the near-term, Regeneron may potentially have three marketed products in the next 6-18 months, including EYLEA for wet AMD (PDUFA date August 20), with a quick label expansion opportunity in CRVO (sBLA submission expected 2H11), ARCALYST for gouty flare prevention (sBLA submission expected mid-2011), and ZALTRAP for 2nd line mCRC (BLA submission expected 2H11). In the long-term, we believe the Company’s evergreen mAb platform will serve to drive growth: we favor REGN727 (PCSK9 mAb) with Phase 2 data expected in 2H11."

For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $54.02 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Globant S.A. (GLOB) PT Lowered to $45 at Needham
• Nu Holdings (Nubank) (NU) PT Raised to $19 at Needham